Dr Mark Kris of MSK in OncLive today 1/4/12, on Cabo in RET-driven NSCLC.
"Another group of patients are those with RET fusion genes. Barely 1 year ago, this abnormality was discovered, and already there were reports at ESMO this year that the drug cabozantinib can effectively treat these patients. "
Interesting overall commentary on the use of TKI's in NSCLC...and some interesting thoughts wrt the recently cancelled tivantinib trial. If I read Dr Kris correctly, it is his belief that the P3 MARQUEE trial wasn't clearly supported by earlier P2 data, and perhaps the late stage trial should not even have been initiated.
Though not mentioned specifically in this article, Cabo's proven effectiveness in erlotinib resistant patient pops make NSCLC another indication to watch for in future NCCN recommendations where RET and EGFR are the diagnosed drivers of tumor growth.
"New Targets, Improved Survival in Lung Cancer" on MedScape was recorded during the 2012 ASCO. It is comprised of a highly informative interview/discussion between Drs Mark Kris & Giorgo Scagliotti...
As this discussion was limited to currently approved drugs as of June 2012, Cabo is not mentioned...but Cabo's intended targets are irrefutably witnessed. This conversation is great prelude to Dr Kris' more current OncLive commentary.
Thanks Wilderguide and Dr. Vinmantoo for something we non-oncologists also need to know. Cabozinitib trials must expand to include cancers other than MTC. We will see what the management has to say on December 9.